Which IL-5 targeted monoclonal antibodies have shown efficacy in treating asthma with eosinophilia?

Mepolizumab and reslizumab are both targeted monoclonal antibodies specifically designed to inhibit IL-5, a key cytokine involved in the growth, activation, and survival of eosinophils. Eosinophils play a significant role in the pathophysiology of asthma, particularly in patients with eosinophilic asthma. By blocking IL-5, these therapies effectively reduce eosinophil levels, leading to improved asthma control and reduction in exacerbations.

Mepolizumab has been shown to reduce asthma exacerbations and improve lung function in patients with high eosinophil counts. Similarly, reslizumab is also approved for use in patients with severe asthma associated with eosinophilic inflammation. Their direct action on the IL-5 pathway is what makes them effective in treating this specific subset of asthma patients.

Other options, such as the antibody therapies mentioned in the incorrect responses, either do not specifically target IL-5 or may not be indicated for asthma treatment. Understanding the specific mechanisms and indications for these therapies helps in recognizing their appropriate clinical application in managing eosinophilic asthma.